GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lupin Ltd (NSE:LUPIN) » Definitions » Cyclically Adjusted PS Ratio

Lupin (NSE:LUPIN) Cyclically Adjusted PS Ratio : 3.77 (As of May. 17, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Lupin Cyclically Adjusted PS Ratio?

As of today (2024-05-17), Lupin's current share price is ₹1662.95. Lupin's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₹441.53. Lupin's Cyclically Adjusted PS Ratio for today is 3.77.

The historical rank and industry rank for Lupin's Cyclically Adjusted PS Ratio or its related term are showing as below:

NSE:LUPIN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.48   Med: 2.34   Max: 3.78
Current: 3.64

During the past years, Lupin's highest Cyclically Adjusted PS Ratio was 3.78. The lowest was 1.48. And the median was 2.34.

NSE:LUPIN's Cyclically Adjusted PS Ratio is ranked worse than
69.75% of 747 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs NSE:LUPIN: 3.64

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Lupin's adjusted revenue per share data for the three months ended in Mar. 2024 was ₹106.955. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹441.53 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Lupin Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Lupin's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lupin Cyclically Adjusted PS Ratio Chart

Lupin Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.62 2.70 1.87 1.54 3.66

Lupin Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.54 2.09 2.68 2.99 3.66

Competitive Comparison of Lupin's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Lupin's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lupin's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lupin's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lupin's Cyclically Adjusted PS Ratio falls into.



Lupin Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Lupin's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1662.95/441.53
=3.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lupin's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Lupin's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=106.955/153.0345*153.0345
=106.955

Current CPI (Mar. 2024) = 153.0345.

Lupin Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 74.170 94.103 120.619
201409 70.364 96.780 111.263
201412 70.426 96.780 111.361
201503 63.897 97.163 100.640
201506 69.777 99.841 106.953
201509 73.534 101.753 110.593
201512 78.385 102.901 116.574
201603 92.717 102.518 138.404
201606 98.628 105.961 142.444
201609 94.727 105.961 136.810
201612 97.268 105.196 141.501
201703 93.857 105.196 136.539
201706 83.885 107.109 119.853
201709 85.485 109.021 119.996
201712 85.632 109.404 119.782
201803 89.219 109.786 124.365
201806 83.400 111.317 114.656
201809 85.724 115.142 113.935
201812 84.608 115.142 112.452
201903 83.847 118.202 108.555
201906 83.978 120.880 106.317
201909 84.479 123.175 104.958
201912 82.110 126.235 99.542
202003 81.983 124.705 100.607
202006 76.251 127.000 91.882
202009 83.156 130.118 97.802
202012 86.078 130.889 100.642
202103 82.586 131.771 95.913
202106 93.034 134.084 106.183
202109 88.196 135.847 99.355
202112 89.764 138.161 99.428
202203 84.179 138.822 92.797
202206 79.297 142.347 85.250
202209 89.877 144.661 95.079
202212 92.928 145.763 97.564
202303 94.564 146.865 98.537
202306 103.805 150.280 105.708
202309 108.131 151.492 109.232
202312 111.106 152.924 111.186
202403 106.955 153.035 106.955

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lupin  (NSE:LUPIN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Lupin Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Lupin's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lupin (NSE:LUPIN) Business Description

Industry
Traded in Other Exchanges
Address
Off. Western Express Highway, 3rd floor, Kalpataru Inspire, Santacruz (East), Mumbai, MH, IND, 400 055
Lupin Ltd is a specialty and generic drug manufacturing company. The company's global formulations business develops and delivers a wide range of branded and generic formulations across the globe. The operations of the company are limited to one segment, namely pharmaceuticals and related products. The company also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India.

Lupin (NSE:LUPIN) Headlines

No Headlines